

Novel Drug Targets or Drug Candidates Based on Human Genetics

This campaign has been commissioned by an international Japanese pharmaceutical company who combat diseases with a combination of ground-breaking technology and biology, with an extensive track record of academic collaboration. They are seeking **promising drug targets** or **drug candidates** that are **secured by human genetic information** and are unprecedented (i.e. no competitors are reported).



Definition of promising drug target:

- Expressed in limited tissue or cells, which play an important role in disease pathophysiology
- Our client is interested in **all disease areas and all modalities**, including drug conjugates

Out of Scope:

- Ultra-rare diseases (e.g. fewer than one patient per 50,000 people), especially whose pathology is not related to common diseases
- Phenotypic screening studies in which drug targets are not identified, e.g. unaccompanied machine learning approaches
- Non-mammalian models are of less interest
- Diseases caused by somatic mutations are of less interest






Stage of Development:

Preference for **pre-clinical**, however, all stages of development will be considered, from basic research to phase 1 clinical trials.

Submission Information:

Submission of one-page summaries of Research Projects, Technology Briefs, Academic Profiles, Centres of Excellence and Spin-Outs are encouraged. Alternatively, please fill out an application form available [here](#).

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Spinout companies
-  Research projects

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **7th December 2020 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk